SpyGlass Pharma, Inc. (SGP) stock
SGPNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$32.88−0.44 (-1.32%)
Close on Nov 13, 2026Market cap $1.10BP/E –Yield –
SpyGlass Pharma r&d expenses
Research and development expenses are spending on new products and technology.
SpyGlass Pharma's R&D Expenses for the twelve months ending Sep 30, 2026 was $37.22M. For fiscal 2025 it was $29.18M, up 46.0% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.18M | +46.0% |
| FY2024 | Dec 31, 2024 | $19.98M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $10.03M | +24.0% |
| Q2 FY2026 | Jun 30, 2026 | $10.94M | +49.2% |
| Q1 FY2026 | Mar 31, 2026 | $8.54M | +41.1% |
| Q4 FY2025 | Dec 31, 2025 | $7.71M | – |
| Q3 FY2025 | Sep 30, 2025 | $8.09M | – |
| Q2 FY2025 | Jun 30, 2025 | $7.33M | – |
| Q1 FY2025 | Mar 31, 2025 | $6.05M | – |
See a number that looks wrong?